AbbVie’s Rinvoq Achieves Strong Phase 3 Results in Alopecia Areata, Clearing Key Efficacy Milestone

Rinvoq (upadacitinib) achieved up to 54.3% hair regrowth (≥80% scalp coverage) in a pivotal Phase 3 trial for severe alopecia areata at the 30 mg dose; the 15 mg dose achieved 44.6% versus 3.4% for placebo345.

A substantial proportion of patients—36.0% (15 mg) and 47.1% (30 mg)—achieved ≥90% scalp hair coverage at 24 weeks, compared with 1.4% for placebo235.

Other key secondary endpoints, including improvement in eyebrows and eyelashes and the percentage of patients achieving complete scalp hair coverage, were also met at both doses45.

The safety profile of Rinvoq in this population was consistent with its approved uses, with no new safety signals reported34.

Rinvoq is now positioned as a leading JAK inhibitor in the hair loss treatment landscape, with analysts describing the results as 'impressive' and projecting a competitive advantage over other therapies2.

Sources:

2. https://www.biospace.com/drug-development/abbvie-carves-out-niche-for-rinvoq-with-impressive-alopecia-areata-data

3. https://scholarsinmedicine.com/latest-news/896

4. https://www.prnewswire.com/news-releases/abbvie-announces-positive-topline-results-from-phase-3-up-aa-trial-evaluating-upadacitinib-rinvoq-for-alopecia-areata-302517362.html

5. https://pmlive.com/pharma_news/abbvie-shares-promising-phase-3-results-for-rinvoq-in-severe-alopecia-areata/